Discover the price reduction of ENFINIA™ DNA products by 25%, improving access to high-quality DNA for researchers.

Elegen, a leader in next-generation cell-free DNA manufacturing, today announced a 25% reduction in price for ENFINIAtm DNA, making industry-leading long, complex, NGS-verified DNA more accessible to ...

EffiXTM is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Phase 3 Ovarian Cancer Trial to Initiate in March 2025 Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial ...

The ability to control gene expression across a wide range is crucial for many fields, including bioengineering, disease detection, and environmental monitoring. Research led by Lingchong You, Ph.D., ...

Imunon has reported new immunogenicity and safety data from its proof-of-concept Phase I trial’s ongoing analyses of the IMNN-101 DNA plasmid vaccine. The investigational vaccine, based on the company ...

Credit: BaLL LunLa / Shutterstock. Imunon has reported new immunogenicity and safety data from its proof-of-concept Phase I trial’s ongoing analyses of the IMNN-101 DNA plasmid vaccine. The ...

Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® ...

According to Statifacts, the U.S. viral vector and plasmid DNA manufacturing market size is calculated at USD 2,480 million in 2025 and is forecasted to reach around USD 10,660 million by 2034, ...